Literature DB >> 23435293

Performance of creatinine and cystatin C-based glomerular filtration rate estimating equations in a European HIV-positive cohort.

Amandine Gagneux-Brunon1, Pierre Delanaye, Nicolas Maillard, Anne Fresard, Thierry Basset, Eric Alamartine, Frédéric Lucht, Hans Pottel, Christophe Mariat.   

Abstract

OBJECTIVE: To validate glomerular filtration rate (GFR) estimating equations in white HIV-infected patients based on serum creatinine and/or serum cystatin C.
DESIGN: Single-center, cross-sectional evaluation of the predictive performance of GFR estimators.
METHODS: GFR was measured by iohexol plasma clearance. Serum creatinine (Scr) and serum cystatin C (Scyst) were measured by traceable and standardized methods. We evaluated the performance of the Modification of Diet in Renal Disease (MDRD) and the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equations. We also studied the performance of the cystatin C-based equation (CKD-EPI Scyst) and the combined cystatin and creatinine-based equation (CKD-EPI combined), as recently proposed by the CKD-EPI group.
RESULTS: Two hundred and three participants (18% of women) were included. Mean age was 49 ± 10 years. Mean measured GFR (mGFR) was 95 ± 24 ml/min per 1.73 m². CKD-EPI and CKD-EPI combined significantly outperformed the MDRD equation. The percentage of estimating results within 30% of mGFR was 75, 82 and 81% for the MDRD, CKD-EPI and CKD-EPI combined equation, respectively. Results favoring the CKD-EPI and CKD-EPI combined equation were especially observed for patients with mGFR over 90 ml/min per 1.73 m².
CONCLUSION: In our European HIV cohort, we confirmed that the creatinine-based CKD-EPI equation should replace the MDRD study equation. However, global performance of this equation remains worse than the performance observed in the general population. This lesser performance is particularly relevant in patients with measured GFR under and around 60 ml/min per 1.73 m². Moreover, the specific interest of Scyst-based equations is not confirmed in this population.
© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23435293     DOI: 10.1097/QAD.0b013e32835fac30

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  21 in total

1.  Estimating glomerular filtration rate for the full age spectrum from serum creatinine and cystatin C.

Authors:  Hans Pottel; Pierre Delanaye; Elke Schaeffner; Laurence Dubourg; Bjørn Odvar Eriksen; Toralf Melsom; Edmund J Lamb; Andrew D Rule; Stephen T Turner; Richard J Glassock; Vandréa De Souza; Luciano Selistre; Karolien Goffin; Steven Pauwels; Christophe Mariat; Martin Flamant; Natalie Ebert
Journal:  Nephrol Dial Transplant       Date:  2017-03-01       Impact factor: 5.992

Review 2.  Kidney Disease and HIV Infection.

Authors:  Christina M Wyatt
Journal:  Top Antivir Med       Date:  2017 Feb/Mar

3.  Plasma Cystatin C Associates With HIV-Associated Neurocognitive Disorder but Is a Poor Diagnostic Marker in Antiretroviral Therapy-Treated Individuals.

Authors:  Robert C Kalayjian; Kevin R Robertson; Jeffrey M Albert; Carl J Fichtenbaum; Todd T Brown; Babafemi O Taiwo
Journal:  J Acquir Immune Defic Syndr       Date:  2019-06-01       Impact factor: 3.731

4.  Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s.

Authors:  Chris T Longenecker; Douglas Kitch; Paul E Sax; Eric S Daar; Camlin Tierney; Samir K Gupta; Grace A McComsey
Journal:  J Acquir Immune Defic Syndr       Date:  2015-06-01       Impact factor: 3.731

5.  Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.

Authors:  Gregory M Lucas; Michael J Ross; Peter G Stock; Michael G Shlipak; Christina M Wyatt; Samir K Gupta; Mohamed G Atta; Kara K Wools-Kaloustian; Paul A Pham; Leslie A Bruggeman; Jeffrey L Lennox; Patricio E Ray; Robert C Kalayjian
Journal:  Clin Infect Dis       Date:  2014-09-17       Impact factor: 9.079

6.  Kidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Authors:  A C Achhra; A Mocroft; M J Ross; L Ryom; G M Lucas; H Furrer; J Neuhaus; C Somboonwit; M Kelly; J M Gatell; C M Wyatt
Journal:  HIV Med       Date:  2015-04       Impact factor: 3.180

7.  An estimated glomerular filtration rate equation for the full age spectrum.

Authors:  Hans Pottel; Liesbeth Hoste; Laurence Dubourg; Natalie Ebert; Elke Schaeffner; Bjørn Odvar Eriksen; Toralf Melsom; Edmund J Lamb; Andrew D Rule; Stephen T Turner; Richard J Glassock; Vandréa De Souza; Luciano Selistre; Christophe Mariat; Frank Martens; Pierre Delanaye
Journal:  Nephrol Dial Transplant       Date:  2016-02-29       Impact factor: 5.992

8.  Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV trial.

Authors:  Chris T Longenecker; Corrilynn O Hileman; Nicholas T Funderburg; Grace A McComsey
Journal:  Clin Infect Dis       Date:  2014-07-11       Impact factor: 9.079

9.  Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV.

Authors:  Sanjiv M Baxi; Rebecca Scherzer; Ruth M Greenblatt; Howard Minkoff; Anjali Sharma; Mardge Cohen; Mary A Young; Alison G Abraham; Michael G Shlipak
Journal:  AIDS       Date:  2016-02-20       Impact factor: 4.177

10.  Factors associated with iohexol-based glomerular filtration rate slope over 36 months in HIV-negative and HIV-positive individuals.

Authors:  Gregory M Lucas; Mohamed G Atta; Katie Zook; Allison M McFall; Shruti H Mehta; Derek M Fine; James H Stein; George J Schwartz
Journal:  AIDS       Date:  2016-02-20       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.